Alnylam Announces FDA Granted Priority Review of the Givosiran NDA for the Treatment of Acute…
Alnylam Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for givosiran, an investigational RNAi…
Read More...
Read More...
